- Home
- EDSA vs SNTI Comparison
EDSA vs SNTI Comparison
Compare EDSA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- SNTI
- Stock Information
- Founded
- EDSA 2015
- SNTI 2016
- Country
- EDSA Canada
- SNTI United States
- Employees
- EDSA N/A
- SNTI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- SNTI Health Care
- Exchange
- EDSA Nasdaq
- SNTI Nasdaq
- Market Cap
- EDSA 6.1M
- SNTI 18.2M
- IPO Year
- EDSA N/A
- SNTI N/A
- Fundamental
- Price
- EDSA $1.73
- SNTI $3.97
- Analyst Decision
- EDSA Strong Buy
- SNTI Strong Buy
- Analyst Count
- EDSA 1
- SNTI 1
- Target Price
- EDSA $21.00
- SNTI $12.00
- AVG Volume (30 Days)
- EDSA 30.8K
- SNTI 7.2M
- Earning Date
- EDSA 02-07-2025
- SNTI 11-14-2024
- Dividend Yield
- EDSA N/A
- SNTI N/A
- EPS Growth
- EDSA N/A
- SNTI N/A
- EPS
- EDSA N/A
- SNTI N/A
- Revenue
- EDSA N/A
- SNTI N/A
- Revenue This Year
- EDSA N/A
- SNTI $254.47
- Revenue Next Year
- EDSA N/A
- SNTI $169.66
- P/E Ratio
- EDSA N/A
- SNTI N/A
- Revenue Growth
- EDSA N/A
- SNTI N/A
- 52 Week Low
- EDSA $1.55
- SNTI $1.52
- 52 Week High
- EDSA $5.99
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- EDSA 31.51
- SNTI 47.37
- Support Level
- EDSA $1.73
- SNTI $3.60
- Resistance Level
- EDSA $1.99
- SNTI $5.96
- Average True Range (ATR)
- EDSA 0.19
- SNTI 1.02
- MACD
- EDSA 0.02
- SNTI -0.29
- Stochastic Oscillator
- EDSA 18.00
- SNTI 5.74
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.